{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,25]],"date-time":"2026-08-25T01:17:22Z","timestamp":1787620642908,"version":"build-2736575974"},"reference-count":51,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2018,3,22]],"date-time":"2018-03-22T00:00:00Z","timestamp":1521676800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Neural Transm"],"published-print":{"date-parts":[[2018,11]]},"DOI":"10.1007\/s00702-018-1876-2","type":"journal-article","created":{"date-parts":[[2018,3,22]],"date-time":"2018-03-22T15:54:46Z","timestamp":1521734086000},"page":"1751-1757","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":68,"title":["Monoamine oxidase-B inhibitors in the treatment of Parkinson\u2019s disease: clinical\u2013pharmacological aspects"],"prefix":"10.1007","volume":"125","author":[{"given":"Peter","family":"Riederer","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"M\u00fcller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2018,3,22]]},"reference":[{"key":"1876_CR1","doi-asserted-by":"publisher","first-page":"e266","DOI":"10.1212\/NXI.0000000000000266","volume":"3","author":"D Apetauerova","year":"2016","unstructured":"Apetauerova D, Scala SA, Hamill RW, Simon DK, Pathak S, Ruthazer R, Standaert DG, Yacoubian TA (2016) CoQ10 in progressive supranuclear palsy: a randomized, placebo-controlled, double-blind trial. Neurol Neuroimmunol Neuroinflamm 3:e266","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"key":"1876_CR2","doi-asserted-by":"crossref","first-page":"P01","DOI":"10.1212\/WNL.80.7_supplement.P01.061","volume":"80","author":"P Barone","year":"2013","unstructured":"Barone P, Fernandez HH, Ferreira J, M\u00fcller T, Saint-Hilaire M, Stacy M, Tolosa E, Anand R (2013) Safinamide as an add-on therapy to a stable dose of a single dopamine agonist: results from a randomized, placebo-controlled, 24-week multicenter trial in early idiopathic Parkinson disease (PD) patients (MOTION Study). Neurology 80:P01\u2013P061","journal-title":"Neurology"},{"key":"1876_CR3","doi-asserted-by":"publisher","first-page":"505","DOI":"10.1016\/j.parkreldis.2007.11.007","volume":"14","author":"AL Bartels","year":"2008","unstructured":"Bartels AL, van Berckel BN, Lubberink M, Luurtsema G, Lammertsma AA, Leenders KL (2008a) Blood\u2013brain barrier P-glycoprotein function is not impaired in early Parkinson\u2019s disease. Parkinsonism Relat Disord 14:505\u2013508","journal-title":"Parkinsonism Relat Disord"},{"key":"1876_CR4","doi-asserted-by":"publisher","first-page":"1001","DOI":"10.1007\/s00702-008-0030-y","volume":"115","author":"AL Bartels","year":"2008","unstructured":"Bartels AL, Willemsen AT, Kortekaas R, de Jong BM, de Vries R, de Klerk O, van Oostrom JC, Portman A, Leenders KL (2008b) Decreased blood\u2013brain barrier P-glycoprotein function in the progression of Parkinson\u2019s disease, PSP and MSA. J Neural Transm 115:1001\u20131009","journal-title":"J Neural Transm"},{"key":"1876_CR5","doi-asserted-by":"publisher","first-page":"543","DOI":"10.1001\/jamaneurol.2014.131","volume":"71","author":"MF Beal","year":"2014","unstructured":"Beal MF, Oakes D, Shoulson I, Henchcliffe C, Galpern WR, Haas R, Juncos JL, Nutt JG, Voss TS, Ravina B, Shults CM, Helles K, Snively V, Lew MF, Griebner B, Watts A, Gao S, Pourcher E, Bond L, Kompoliti K, Agarwal P, Sia C, Jog M, Cole L, Sultana M, Kurlan R, Richard I, Deeley C, Waters CH, Figueroa A, Arkun A, Brodsky M, Ondo WG, Hunter CB, Jimenez-Shahed J, Palao A, Miyasaki JM, So J, Tetrud J, Reys L, Smith K, Singer C, Blenke A, Russell DS, Cotto C, Friedman JH, Lannon M, Zhang L, Drasby E, Kumar R, Subramanian T, Ford DS, Grimes DA, Cote D, Conway J, Siderowf AD, Evatt ML, Sommerfeld B, Lieberman AN, Okun MS, Rodriguez RL, Merritt S, Swartz CL, Martin WR, King P, Stover N, Guthrie S, Watts RL, Ahmed A, Fernandez HH, Winters A, Mari Z, Dawson TM, Dunlop B, Feigin AS, Shannon B, Nirenberg MJ, Ogg M, Ellias SA, Thomas CA, Frei K, Bodis-Wollner I, Glazman S, Mayer T, Hauser RA, Pahwa R, Langhammer A, Ranawaya R, Derwent L, Sethi KD, Farrow B, Prakash R, Litvan I, Robinson A, Sahay A, Gartner M, Hinson VK, Markind S, Pelikan M, Perlmutter JS, Hartlein J, Molho E, Evans S, Adler CH, Duffy A, Lind M, Elmer L, Davis K, Spears J, Wilson S, Leehey MA, Hermanowicz N, Niswonger S, Shill HA, Obradov S, Rajput A, Cowper M, Lessig S, Song D, Fontaine D, Zadikoff C, Williams K, Blindauer KA, Bergholte J, Propsom CS, Stacy MA, Field J, Mihaila D, Chilton M, Uc EY, Sieren J, Simon DK, Kraics L, Silver A, Boyd JT, Hamill RW, Ingvoldstad C, Young J, Thomas K, Kostyk SK, Wojcieszek J, Pfeiffer RF, Panisset M, Beland M, Reich SG, Cines M, Zappala N, Rivest J, Zweig R, Lumina LP, Hilliard CL, Grill S, Kellermann M, Tuite P, Rolandelli S, Kang UJ, Young J, Rao J, Cook MM, Severt L, Boyar K (2014) A randomized clinical trial of high-dosage coenzyme Q10 in early Parkinson disease: no evidence of benefit. JAMA Neurol 71:543\u2013552","journal-title":"JAMA Neurol"},{"key":"1876_CR6","doi-asserted-by":"publisher","first-page":"250","DOI":"10.1097\/00002826-199506000-00005","volume":"18","author":"S Calzetti","year":"1995","unstructured":"Calzetti S, Negrotti A, Cassio A (1995) l-deprenyl as an adjunct to low-dose bromocriptine in early Parkinson\u2019s disease: a short-term, double-blind, and prospective follow-up study. Clin Neuropharmacol 18:250\u2013257","journal-title":"Clin Neuropharmacol"},{"key":"1876_CR7","first-page":"S21","volume":"54","author":"MC Rijk de","year":"2000","unstructured":"de Rijk MC, Launer LJ, Berger K, Breteler MM, Dartigues JF, Baldereschi M, Fratiglioni L, Lobo A, Martinez-Lage J, Trenkwalder C, Hofman A (2000) Prevalence of Parkinson\u2019s disease in Europe: a collaborative study of population-based cohorts. Neurologic Diseases in the Elderly Research Group. Neurology 54:S21\u2013S23","journal-title":"Neurology"},{"key":"1876_CR8","doi-asserted-by":"publisher","first-page":"739","DOI":"10.1001\/archneurol.2010.101","volume":"67","author":"F Dutheil","year":"2010","unstructured":"Dutheil F, Beaune P, Tzourio C, Loriot MA, Elbaz A (2010) Interaction between ABCB1 and professional exposure to organochlorine insecticides in Parkinson disease. Arch Neurol 67:739\u2013745","journal-title":"Arch Neurol"},{"key":"1876_CR9","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1212\/WNL.52.1.120","volume":"52","author":"A Ekesbo","year":"1999","unstructured":"Ekesbo A, Rydin E, Torstenson R, Sydow O, Laengstrom B, Tedroff J (1999) Dopamine autoreceptor function is lost in advanced Parkinson\u2019s disease. Neurology 52:120\u2013125","journal-title":"Neurology"},{"key":"1876_CR10","doi-asserted-by":"publisher","first-page":"371","DOI":"10.1097\/00004714-198212000-00002","volume":"2","author":"RW Fuller","year":"1982","unstructured":"Fuller RW, Clemens JA, Hynes MD III (1982) Degree of selectivity of pergolide as an agonist at presynaptic versus postsynaptic dopamine receptors: implications for prevention or treatment of tardive dyskinesia. J Clin Psychopharmacol 2:371\u2013375","journal-title":"J Clin Psychopharmacol"},{"key":"1876_CR11","doi-asserted-by":"publisher","first-page":"840","DOI":"10.1136\/jnnp-2013-306787","volume":"85","author":"PJ Garcia-Ruiz","year":"2014","unstructured":"Garcia-Ruiz PJ, Martinez Castrillo JC, Alonso-Canovas A, Herranz BA, Vela L, Sanchez AP, Mata M, Olmedilla GN, Mahillo Fernandez I (2014) Impulse control disorder in patients with Parkinson\u2019s disease under dopamine agonist therapy: a multicentre study. J Neurol Neurosurg Psychiatry 85:840\u2013844","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"1876_CR12","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1007\/s007020050003","volume":"107","author":"ME G\u00f6tz","year":"2000","unstructured":"G\u00f6tz ME, Gerstner A, Harth R, Dirr A, Janetzky B, Kuhn W, Riederer P, Gerlach M (2000) Altered redox state of platelet coenzyme Q10 in Parkinson\u2019s disease. J Neural Transm 107:41\u201348","journal-title":"J Neural Transm"},{"key":"1876_CR13","doi-asserted-by":"publisher","first-page":"250","DOI":"10.1016\/j.jpsychores.2011.03.011","volume":"71","author":"AM Gregory","year":"2011","unstructured":"Gregory AM, Buysse DJ, Willis TA, Rijsdijk FV, Maughan B, Rowe R, Cartwright S, Barclay NL, Eley TC (2011) Associations between sleep quality and anxiety and depression symptoms in a sample of young adult twins and siblings. J Psychosom Res 71:250\u2013255","journal-title":"J Psychosom Res"},{"key":"1876_CR14","doi-asserted-by":"publisher","first-page":"1028","DOI":"10.1002\/mds.25877","volume":"29","author":"RA Hauser","year":"2014","unstructured":"Hauser RA, Silver D, Choudhry A, Eyal E, Isaacson S (2014) Randomized, controlled trial of rasagiline as an add-on to dopamine agonists in Parkinson\u2019s disease. Mov Disord 29:1028\u20131034","journal-title":"Mov Disord"},{"key":"1876_CR15","doi-asserted-by":"publisher","first-page":"182","DOI":"10.1016\/S0304-3940(01)01574-9","volume":"300","author":"P H\u00e4ussermann","year":"2001","unstructured":"H\u00e4ussermann P, Kuhn W, Przuntek H, M\u00fcller T (2001) Integrity of the blood-cerebrospinal fluid barrier in early Parkinson\u2019s disease. Neurosci Lett 300:182\u2013184","journal-title":"Neurosci Lett"},{"key":"1876_CR16","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1097\/WNF.0b013e31823b1da8","volume":"35","author":"A Korchounov","year":"2012","unstructured":"Korchounov A, Winter Y, Rossy W (2012) Combined beneficial effect of rasagiline on motor function and depression in de novo PD. Clin Neuropharmacol 35:121\u2013124","journal-title":"Clin Neuropharmacol"},{"key":"1876_CR17","doi-asserted-by":"publisher","first-page":"161","DOI":"10.2165\/80-000000000-00000","volume":"28","author":"N Kovacs","year":"2011","unstructured":"Kovacs N, Janszky J, Nagy F (2011) Cost effectiveness of rasagiline and pramipexole as treatment strategies in early Parkinson\u2019s disease in the UK setting: an economic Markov model evaluation. Drugs Aging 28:161\u2013162","journal-title":"Drugs Aging"},{"key":"1876_CR18","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1093\/jat\/27.3.135","volume":"27","author":"R Kronstrand","year":"2003","unstructured":"Kronstrand R, Ahlner J, Dizdar N, Larson G (2003) Quantitative analysis of desmethylselegiline, methamphetamine, and amphetamine in hair and plasma from Parkinson patients on long-term selegiline medication. J Anal Toxicol 27:135\u2013141","journal-title":"J Anal Toxicol"},{"key":"1876_CR19","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1097\/00002826-199710000-00006","volume":"20","author":"K Laine","year":"1997","unstructured":"Laine K, Anttila M, Heinonen E, Helminen A, Huupponen R, Maki-Ikola O, Reinikainen K, Scheinin M (1997) Lack of adverse interactions between concomitantly administered selegiline and citalopram. Clin Neuropharmacol 20:419\u2013433","journal-title":"Clin Neuropharmacol"},{"key":"1876_CR20","first-page":"467","volume":"3","author":"S Lecht","year":"2007","unstructured":"Lecht S, Haroutiunian S, Hoffman A, Lazarovici P (2007) Rasagiline\u2014a novel MAO B inhibitor in Parkinson\u2019s disease therapy. Ther Clin Risk Manag 3:467\u2013474","journal-title":"Ther Clin Risk Manag"},{"key":"1876_CR21","doi-asserted-by":"publisher","first-page":"L317","DOI":"10.1016\/0024-3205(96)00525-5","volume":"59","author":"A Mao","year":"1996","unstructured":"Mao A, Freeman KA, Tallarida RJ (1996) Transient loss of dopamine autoreceptor control in the presence of highly potent dopamine agonists. Life Sci 59:L317\u2013L324","journal-title":"Life Sci"},{"key":"1876_CR22","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1097\/WNF.0000000000000239","volume":"40","author":"Y Mizuno","year":"2017","unstructured":"Mizuno Y, Hattori N, Kondo T, Nomoto M, Origasa H, Takahashi R, Yamamoto M, Yanagisawa N (2017) A Randomized double-blind placebo-controlled phase III trial of selegiline monotherapy for early Parkinson disease. Clin Neuropharmacol 40:201\u2013207","journal-title":"Clin Neuropharmacol"},{"key":"1876_CR23","doi-asserted-by":"publisher","first-page":"1357","DOI":"10.1007\/s00702-014-1213-3","volume":"121","author":"S Muhlack","year":"2014","unstructured":"Muhlack S, Herrmann L, Salmen S, M\u00fcller T (2014) Fewer fluctuations, higher maximum concentration and better motor response of levodopa with catechol-O-methyltransferase inhibition. J Neural Transm 121:1357\u20131366","journal-title":"J Neural Transm"},{"key":"1876_CR24","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/2047-9158-1-10","volume":"1","author":"T M\u00fcller","year":"2012","unstructured":"M\u00fcller T (2012) Drug therapy in patients with Parkinson\u2019s disease. Transl Neurodegener 1:1\u201310","journal-title":"Transl Neurodegener"},{"key":"1876_CR25","doi-asserted-by":"publisher","first-page":"1423","DOI":"10.1517\/17425255.2014.943182","volume":"10","author":"T M\u00fcller","year":"2014","unstructured":"M\u00fcller T (2014) Pharmacokinetic\/pharmacodynamic evaluation of rasagiline mesylate for Parkinson\u2019s disease. Expert Opin Drug Metab Toxicol 10:1423\u20131432","journal-title":"Expert Opin Drug Metab Toxicol"},{"key":"1876_CR26","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1007\/s40262-016-0449-5","volume":"56","author":"T M\u00fcller","year":"2017","unstructured":"M\u00fcller T, Foley P (2017) Clinical pharmacokinetics and pharmacodynamics of safinamide. Clin Pharmacokinet 56:251\u2013261","journal-title":"Clin Pharmacokinet"},{"key":"1876_CR27","doi-asserted-by":"publisher","first-page":"1115","DOI":"10.1097\/00006231-199712000-00002","volume":"18","author":"T M\u00fcller","year":"1997","unstructured":"M\u00fcller T, Eising EG, Reiners C, Przuntek H, Jacob M, Kuhn W (1997) 2-[123I]-iodolisuride SPET visualizes dopaminergic loss in de-novo parkinsonian patients: is it a marker of striatal pre-synaptic degeneration? Nucl Med Commun 18:1115\u20131121","journal-title":"Nucl Med Commun"},{"key":"1876_CR28","doi-asserted-by":"publisher","first-page":"761","DOI":"10.1007\/s00702-012-0927-3","volume":"120","author":"T M\u00fcller","year":"2013","unstructured":"M\u00fcller T, Hoffmann JA, Dimpfel W, Oehlwein C (2013) Switch from selegiline to rasagiline is beneficial in patients with Parkinson\u2019s disease. J Neural Transm 120:761\u2013765","journal-title":"J Neural Transm"},{"key":"1876_CR29","doi-asserted-by":"publisher","first-page":"715","DOI":"10.1007\/s00702-017-1701-3","volume":"124","author":"T M\u00fcller","year":"2017","unstructured":"M\u00fcller T, \u00d6hm G, Eilert K, M\u00f6hr K, Rotter S, Haas T, K\u00fcchler M, L\u00fctge S, Marg M, Rothe H (2017) Benefit on motor and non-motor behavior in a specialized unit for Parkinson\u2019s disease. J Neural Transm 124:715\u2013720","journal-title":"J Neural Transm"},{"key":"1876_CR30","doi-asserted-by":"publisher","first-page":"407","DOI":"10.1111\/j.1600-0404.1991.tb03973.x","volume":"83","author":"G Nappi","year":"1991","unstructured":"Nappi G, Martignoni E, Horowski R, Pacchetti C, Rainer E, Bruggi P, Runge I (1991) Lisuride plus selegiline in the treatment of early Parkinson\u2019s disease. Acta Neurol Scand 83:407\u2013410","journal-title":"Acta Neurol Scand"},{"key":"1876_CR31","doi-asserted-by":"publisher","first-page":"1268","DOI":"10.1056\/NEJMoa0809335","volume":"361","author":"CW Olanow","year":"2009","unstructured":"Olanow CW, Rascol O, Hauser R, Feigin PD, Jankovic J, Lang A, Langston W, Melamed E, Poewe W, Stocchi F, Tolosa E (2009) A double-blind, delayed-start trial of rasagiline in Parkinson\u2019s disease. N Engl J Med 361:1268\u20131278","journal-title":"N Engl J Med"},{"key":"1876_CR32","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1002\/ana.410390107","volume":"39","author":"Parkinson Study Group","year":"1996","unstructured":"Parkinson Study Group (1996) Impact of deprenyl and tocopherol treatment on Parkinson\u2019s disease in DATATOP patients requiring levodopa. Ann Neurol 39:37\u201345","journal-title":"Ann Neurol"},{"key":"1876_CR33","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1586\/14737175.2014.877840","volume":"14","author":"M Pilleri","year":"2014","unstructured":"Pilleri M, Antonini A (2014) Novel levodopa formulations in the treatment of Parkinson\u2019s disease. Expert Rev Neurother 14:143\u2013149","journal-title":"Expert Rev Neurother"},{"key":"1876_CR34","doi-asserted-by":"publisher","first-page":"1110","DOI":"10.3109\/03639045.2015.1115868","volume":"42","author":"R Pingili","year":"2016","unstructured":"Pingili R, Vemulapalli S, Mullapudi SS, Nuthakki S, Pendyala S, Kilaru N (2016) Pharmacokinetic interaction study between flavanones (hesperetin, naringenin) and rasagiline mesylate in wistar rats. Drug Dev Ind Pharm 42:1110\u20131117","journal-title":"Drug Dev Ind Pharm"},{"key":"1876_CR35","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1111\/j.1468-1331.1999.tb00007.x","volume":"6","author":"H Przuntek","year":"1999","unstructured":"Przuntek H, Conrad B, Dichgans J, Kraus PH, Krauseneck P, Pergande G, Rinne U, Schimrigk K, Schnitker J, Vogel HP (1999) SELEDO: a 5-year long-term trial on the effect of selegiline in early Parkinsonian patients treated with levodopa. Eur J Neurol 6:141\u2013150","journal-title":"Eur J Neurol"},{"key":"1876_CR36","doi-asserted-by":"publisher","first-page":"803","DOI":"10.1001\/archneur.59.5.803","volume":"59","author":"H Przuntek","year":"2002","unstructured":"Przuntek H, Bittkau S, Bliesath H, Buttner U, Fuchs G, Glass J, Haller H, Klockgether T, Kraus P, Lachenmayer L, M\u00fcller D, M\u00fcller T, Rathay B, Sgonina J, Steinijans V, Teshmar E, Ulm G, Volc D (2002) Budipine provides additional benefit in patients with Parkinson disease receiving a stable optimum dopaminergic drug regimen. Arch Neurol 59:803\u2013806","journal-title":"Arch Neurol"},{"key":"1876_CR37","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1007\/s00702-003-0102-y","volume":"111","author":"H Przuntek","year":"2004","unstructured":"Przuntek H, M\u00fcller T, Riederer P (2004) Diagnostic staging of Parkinson\u2019s disease: conceptual aspects. J Neural Transm 111:201\u2013216","journal-title":"J Neural Transm"},{"key":"1876_CR38","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1016\/S1353-8020(97)00029-1","volume":"3","author":"AH Rajput","year":"1997","unstructured":"Rajput AH, Birdi S (1997) Epidemiology of Parkinson\u2019s disease. Parkinsonism Relat Disord 3:175\u2013186","journal-title":"Parkinsonism Relat Disord"},{"key":"1876_CR39","doi-asserted-by":"publisher","first-page":"1489","DOI":"10.1002\/mds.26724","volume":"31","author":"O Rascol","year":"2016","unstructured":"Rascol O, Hauser RA, Stocchi F, Fitzer-Attas CJ, Sidi Y, Abler V, Olanow CW, Investigators AFU (2016) Long-term effects of rasagiline and the natural history of treated Parkinson\u2019s disease. Mov Disord 31:1489\u20131496","journal-title":"Mov Disord"},{"key":"1876_CR40","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1007\/BF01246964","volume":"43","author":"GP Reynolds","year":"1978","unstructured":"Reynolds GP, Riederer P, Sandler M, Jellinger K, Seeman D (1978) Amphetamine and 2-phenylethylamine in post-mortem Parkinsonian brain after (-)deprenyl administration. J Neural Transm 43:271\u2013277","journal-title":"J Neural Transm"},{"key":"1876_CR41","first-page":"159","volume":"37","author":"P Riederer","year":"1983","unstructured":"Riederer P, Jellinger K, Danielczyk W, Seemann D, Ulm G, Reynolds GP, Birkmayer W, Koppel H (1983) Combination treatment with selective monoamine oxidase inhibitors and dopaminergic agonists in Parkinson\u2019s disease: biochemical and clinical observations. Adv Neural 37:159\u2013176","journal-title":"Adv Neural"},{"key":"1876_CR42","doi-asserted-by":"publisher","first-page":"747","DOI":"10.1016\/S1474-4422(13)70117-0","volume":"12","author":"AH Schapira","year":"2013","unstructured":"Schapira AH, McDermott MP, Barone P, Comella CL, Albrecht S, Hsu HH, Massey DH, Mizuno Y, Poewe W, Rascol O, Marek K (2013) Pramipexole in patients with early Parkinson\u2019s disease (PROUD): a randomised delayed-start trial. Lancet Neurol 12:747\u2013755","journal-title":"Lancet Neurol"},{"key":"1876_CR43","doi-asserted-by":"publisher","first-page":"939","DOI":"10.1111\/j.1471-4159.2010.07132.x","volume":"118","author":"J Sian-H\u00fclsmann","year":"2011","unstructured":"Sian-H\u00fclsmann J, Mandel S, Youdim MB, Riederer P (2011) The relevance of iron in the pathogenesis of Parkinson\u2019s disease. J Neurochem 118:939\u2013957","journal-title":"J Neurochem"},{"key":"1876_CR44","doi-asserted-by":"publisher","first-page":"947","DOI":"10.2174\/1871527314666150317225659","volume":"14","author":"J Sian-H\u00fclsmann","year":"2015","unstructured":"Sian-H\u00fclsmann J, Monoranu C, Strobel S, Riederer P (2015) Lewy bodies: a spectator or salient killer? CNS Neurol Disord Drug Targets 14:947\u2013955","journal-title":"CNS Neurol Disord Drug Targets"},{"issue":"11","key":"1876_CR45","doi-asserted-by":"publisher","first-page":"1735","DOI":"10.1007\/s00702-018-1853-9","volume":"125","author":"\u00c9va Sz\u00f6k\u0151","year":"2018","unstructured":"Sz\u00f6k\u0151 E, T\u00e1bi T, Riederer P, V\u00e9csei L, Magyar K (2018) Pharmacological aspects of the neuroprotective effects of irreversible MAO-B inhibitors, selegiline and rasagiline, in Parkinson\u2019s disease. J Neural Transm (Vienna). https:\/\/doi.org\/10.1007\/s00702-018-1853-9","journal-title":"Journal of Neural Transmission"},{"key":"1876_CR46","doi-asserted-by":"publisher","first-page":"1106","DOI":"10.1001\/archneurol.2009.195","volume":"66","author":"CM Tanner","year":"2009","unstructured":"Tanner CM, Ross GW, Jewell SA, Hauser RA, Jankovic J, Factor SA, Bressman S, Deligtisch A, Marras C, Lyons KE, Bhudhikanok GS, Roucoux DF, Meng C, Abbott RD, Langston JW (2009) Occupation and risk of parkinsonism: a multicenter case-control study. Arch Neurol 66:1106\u20131113","journal-title":"Arch Neurol"},{"key":"1876_CR47","doi-asserted-by":"publisher","first-page":"447","DOI":"10.1093\/sleep\/31.4.447","volume":"31","author":"DJ Taylor","year":"2008","unstructured":"Taylor DJ (2008) Insomnia and depression. Sleep 31:447\u2013448","journal-title":"Sleep"},{"key":"1876_CR48","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1016\/j.sleep.2007.03.004","volume":"8","author":"M Thorpy","year":"2007","unstructured":"Thorpy M (2007) Therapeutic advances in narcolepsy. Sleep Med 8:427\u2013440","journal-title":"Sleep Med"},{"key":"1876_CR49","doi-asserted-by":"publisher","first-page":"1349","DOI":"10.1517\/17425250903193079","volume":"5","author":"S Vautier","year":"2009","unstructured":"Vautier S, Fernandez C (2009) ABCB1: the role in Parkinson\u2019s disease and pharmacokinetics of antiparkinsonian drugs. Expert Opin Drug Metab Toxicol 5:1349\u20131358","journal-title":"Expert Opin Drug Metab Toxicol"},{"key":"1876_CR50","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1016\/j.neulet.2008.06.055","volume":"442","author":"S Vautier","year":"2008","unstructured":"Vautier S, Milane A, Fernandez C, Buyse M, Chacun H, Farinotti R (2008) Interactions between antiparkinsonian drugs and ABCB1\/P-glycoprotein at the blood\u2013brain barrier in a rat brain endothelial cell model. Neurosci Lett 442:19\u201323","journal-title":"Neurosci Lett"},{"key":"1876_CR51","doi-asserted-by":"publisher","first-page":"911","DOI":"10.1016\/j.parkreldis.2015.05.022","volume":"21","author":"A Yoritaka","year":"2015","unstructured":"Yoritaka A, Kawajiri S, Yamamoto Y, Nakahara T, Ando M, Hashimoto K, Nagase M, Saito Y, Hattori N (2015) Randomized, double-blind, placebo-controlled pilot trial of reduced coenzyme Q10 for Parkinson\u2019s disease. Parkinsonism Relat Disord 21:911\u2013916","journal-title":"Parkinsonism Relat Disord"}],"container-title":["Journal of Neural Transmission"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00702-018-1876-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00702-018-1876-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00702-018-1876-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,7,2]],"date-time":"2024-07-02T06:45:56Z","timestamp":1719902756000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00702-018-1876-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,3,22]]},"references-count":51,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2018,11]]}},"alternative-id":["1876"],"URL":"https:\/\/doi.org\/10.1007\/s00702-018-1876-2","relation":{},"ISSN":["0300-9564","1435-1463"],"issn-type":[{"value":"0300-9564","type":"print"},{"value":"1435-1463","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,3,22]]},"assertion":[{"value":"19 December 2017","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 March 2018","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 March 2018","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}]}}